A b s t r a c t
The most important prognostic question regarding meningiomas is prediction of recurrence and, for malignant variants, prediction of survival. 1 Among negative prognostic factors, extent of resection, brain invasion, and increased mitotic activity have been found to be the most predictive. 2, 3 The mitotic index (MI), which is defined as the sum of mitotic figures (MFs) per 10 consecutive high-power fields (HPF) in the area of the highest mitotic activity, has been shown to be one of the most reliable predictors of the likelihood of meningioma recurrence. 3 This is considered in the current World Health Organization (WHO) classification of meningiomas, 2 which distinguishes 3 grades with increasing risk of local recurrence by means of histologic features of prognostic significance. The mitotic thresholds, as suggested by Perry and coworkers, 3 were adopted by the WHO as an objective grading criterion: benign (WHO grade I) meningiomas do not exceed 4 mitoses per 10 HPF, atypical (WHO grade II) meningiomas exhibit an MI of 4 or more and fewer than 20, and anaplastic (WHO grade III) meningiomas show high mitotic activity with 20 or more mitoses per 10 HPF.
However, reliability and reproducibility of meningioma classification based on the standard MI in H&E-stained slides (H&E MI) are limited owing to several factors. These factors include selection bias of HPF owing to subjective determination of the areas of highest mitotic activity and heterogeneity of mitotic activity in different areas of the tumor. Further factors are the variation in sample size of tumor biopsy and resection samples and cellularity, both of which influence the number of evaluable cells. 4 Distinguishing MFs in H&E-stained slides from similar chromatin changes, ie, in apoptotic cells or secondary to crush, distortion, or karyorrhectic debris, pyknosis, or necrosis, is a subjective task.
The identification of MFs could be facilitated by the use of mitosis-specific staining or labeling techniques. The immunohistochemical labeling of MFs with the mitosis-specific antibody anti-phosphohistone H3 (PHH3) has been suggested as a promising method for identifying MFs. 5 Anti-PHH3 antibodies specifically detect the core protein histone H3 only when phosphorylated at serine 10 (Ser10) or serine 28 (Ser28). The phosphorylation of histone H3 is a rare event in interphase cells but a process almost exclusively occurring during mitosis. [6] [7] [8] An antibody highly specific for the phosphorylated form of the amino terminus of histone H3 (Ser10) was introduced in 1997 by Hendzel et al, 8 and immunohistochemical studies have documented tight correlation between H3 phosphorylation and mitotic chromosome condensation initiating during early prophase, whereas no phosphorylation on histone H3 was documented during apoptosis. 9 These findings suggested PHH3 as a mitosis-specific marker. The PHH3 mitosis counting method has been proved as a reliable and facile method for mitosis counting in different types of tumors, 4,10,11 including meningiomas. 12 Until now, no study has shown the correlation between PHH3 MI and recurrence-free survival in a large cohort of meningiomas. We evaluated the results of PHH3 staining for determination of the PHH3 MI in a large retrospective series of 265 meningiomas and compared the results with those for H&E MI and the Ki-67 labeling index (LI). Each of the 3 indicators of proliferation activity was also evaluated for prognostic significance. Based on these findings, we recommend PHH3-specific mitotic thresholds with prognostic and grading implications.
Materials and Methods

Cases and Clinical Data
The retrospective cohort study is based on the data for 265 patients with an initial diagnosis of meningioma, operated on from January 1996 to September 2002 at the Department of Neurosurgery, Saarland University, Medical School, Homburg, Germany. The mean ± SD age was 58.7 ± 13 years (range, 4-88 years). The cohort consisted of 186 females and 79 males (sex distribution, 7:3). For statistical analyses of recurrence-free survival, only patients followed up until recurrence or death or for at least 5 years were considered. Clinical data recorded included dates of birth and death, sex, sites of disease, date of surgery for primary and recurrent tumor resections, extent of resection, and date of recurrence or regrowth as defined radiologically (computed tomography or magnetic resonance imaging). The extent of resection was documented along the guidelines suggested by Simpson. 13 Complete surgical extirpation of the tumor (gross total resection [GTR]) was defined as Simpson grade I or II, corresponding to macroscopically determined complete tumor resection with bipolar coagulation of the dural insertion. Anything less than GTR was considered subtotal resection (STR).
Histomorphologic Examination and MF Counting on H&E-Stained Slides
All available slides from primary meningiomas were reviewed by 2 independent pathologists (Y.-J.K. and W.F.), who were unaware of the patients' outcomes. According to the predominant feature or growth pattern, each tumor was assigned to a histologic pattern and grade consistent with the current WHO criteria. Brain invasion was defined as irregular projections of tumor or tumor cells into adjacent central nervous system parenchyma without an intervening layer of leptomeninges. The MI was obtained by summing the number of MFs in 10 consecutive HPF in the area of highest mitotic activity on H&E-stained slides (H&E MI). When there were discrepancies between the investigators, the case was examined simultaneously by both observers and results recorded after agreement was reached.
We evaluated 215 benign meningiomas (WHO grade I; H&E MI, <4 per 10 HPF), 45 WHO grade II meningiomas (atypical, chordoid, clear cell, or brain-invasive meningiomas; or H&E MI, 4-19 per 10 HPF; or at least 3 of the following criteria: hypercellularity, architectural sheeting, macronucleoli, or small cell formations; meningiomas), and 5 WHO grade III meningiomas (anaplastic, rhabdoid or papillary meningiomas or H&E MI, ≥20 per 10 HPF) were evaluated. Among the rare variants, 2 chordoid types and 1 clear cell meningioma were diagnosed. There were neither papillary nor rhabdoid meningiomas in this series.
MF Counting on Anti-PHH3-Immunostained Slides
In each case, a serial section from the paraffin block containing the area of highest mitotic activity on H&E-stained sections was immunostained with a rabbit monoclonal anti-PHH3 antibody (Ser10, dilution 1:500; Epitomics, Burlingame, CA). The standard procedure included microwave antigen retrieval (10 minutes at 700 W and 30 minutes at 350 W), incubation for 1 hour in a humid chamber at 37°C with the anti-PHH3 antibody, detection of biotinylated secondary antibodies using the streptavidin-horseradish peroxidase method with diaminobenzidine as the chromogen, followed by hematoxylin counterstain. PHH3-labeled MFs were counted in 10 consecutive HPF, in the same manner as in H&E-stained sections. Because histone H3 phosphorylation begins just before prophase, 5 prophase nuclei are also PHH3-labeled. These PHH3+ nuclei were not considered MFs in mitosis counting. PHH3-labeled MFs were also enumerated at low power (LP; objective 10×), and the number of MFs per visual field was recorded as the PHH3 MI LP. Labeled objects, which were not clearly identifiable as MFs at low magnification, were afterwards evaluated and specified at higher magnification.
Ki-67 Immunohistochemical Analysis
Serial sections from the same paraffin blocks used for PHH3 immunohistochemical analysis were immunostained with a monoclonal anti-Ki-67 antibody (clone KiS5, dilution 1:50; DakoCytomation, Glostrup, Denmark) following the standard procedure as described in the preceding sections. The percentages of positively stained tumor cell nuclei were determined in digital images of 5 HPF of the highest labeling region using an automated image analysis device as described by Kim et al. 14 The computed method is described and provided free at the morphometry section of http://www.uniklinikumsaarland.de/neuropathologie.
Statistical Analyses
Correlations in PHH3 MI, H&E MI, and Ki-67 LI values and between PHH3 MI and PHH3 MI LP were determined by linear regression analyses. The interrater agreement in tumor grading based on PHH3 MIs whether obtained at high or low magnification was tested by using κ statistics. Receiver operator characteristics (ROC) were used for determination of the appropriate cutoff levels for each proliferation index regarding discrimination between recurrent and nonrecurrent meningiomas. The discriminatory power was tested by using the Mann-Whitney U test. Survival times and recurrence-free survival times were computed and distributions estimated by using Kaplan-Meier plots. The log-rank test was used for univariate survival analyses. Adjusted for patients' age and extent of tumor resection, Cox proportional hazards modeling techniques were used for multivariate analyses. Statistical analyses were performed using MedCalc software, version 8.1 for Windows (MedCalc Software, Mariakerke, Belgium).
Results
Clinical Data and Follow-up
A GTR was achieved in 238 cases, whereas 27 patients underwent only STR. The median follow-up for all patients studied was 42 months (range, 0-120 months). Of the patients, 99 were followed up until recurrence or death or a minimum of 5 years and were included in survival analyses.
Thirteen patients (mean ± SD age at initial diagnosis, 61 ± 9.6 years; range, 51-78 years) died as a result of disease or postoperative complications after a mean of 11.4 months following primary surgery. Initial diagnoses were WHO grade I meningioma in 9 of these patients, WHO grade II meningioma in 3 patients, and WHO grade III meningioma in 1 patient. The 9 patients with WHO grade I meningiomas and a fatal course were older than the average (median, 68.9 vs 58.7 years), and the tumors were preferentially located at the skull base (7/9 [78%]).
The overall recurrence rate was 12.5% (n = 33), and the relative risk (RR) of recurrence was significantly higher for meningiomas treated by STR (10/27; RR = 37%) than for those treated by GTR (23/238, RR = 9.7%). Recurrences occurred after a mean of 45 months (48 months after GTR and 36 months after STR). The recurrence rate in WHO grade I meningiomas was 6.0% in the GTR subset (11/184) and 9.8% (21/215) in the entire cohort (GTR and STR subset). Recurrences were recorded in 18% (8/45) of WHO grade II meningiomas and 80% (4/5) of anaplastic meningiomas. Brain invasions were recorded in 14 tumors (12 grade II and 2 grade III meningiomas) within 42 cases in which the central nervous system parenchyma was assessable. There was evidence of an increase of median proliferation activity within the subset of brain-invasive meningiomas compared with WHO grade I meningiomas ❚Table 1❚. Four brain-invasive tumors recurred (RR = 29%). (Images 1B-1D) . The correlation between PHH3 MI and PHH3 MI LP was highly significant (correlation coefficient, r = 0.98; regression coefficient, R 2 = 0.95; P < .00001). Corresponding results of the 2 counting methods are plotted ❚Figure 1❚. Results of tumor grading based on these 2 MF counting techniques revealed no differences in tumor grade; thus, the κ statistics revealed a perfect fit of these methods (κ = 1).
Results of mitosis counting on H&E-stained slides and on serial anti-PHH3-immunostained sections are summarized in Table 1 . The correlation between H&E MI and PHH3 MI was also highly significant (r = 0.9; R 2 = 0.77; P < .00001). Corresponding results of H&E and PHH3 counting methods are plotted in a scattergram (Figure 1 ). The linear regression analyses indicated a lower but significant correlation between the Ki-67 LI and the H&E MI (R 2 = 0.5; P < .001) or the PHH3 MI (R 2 = 0.6; P < .001).
The PHH3 counting method was more sensitive in the detection of MFs compared with the traditional H&E-stained MF counts, with mean MF counts of 3.2 vs 1.6 in H&E-stained sections and with increased median MF counts in all 3 grades (Table 1) . If the mitotic thresholds suggested by the WHO were applied to the PHH3 MI results, in 28 cases there would be changes in grade: 27 of WHO grade I meningiomas would have increased in grade to atypical meningiomas (WHO grade II), and 1 atypical meningioma would have increased to an anaplastic meningioma (WHO grade III). Of these, 3 of the WHO grade I meningiomas and the atypical meningioma recurred.
Recurrence-Free Survival Analyses
Results of ROC analysis for H&E MI, PHH3 MI, and Ki-67 LI are specified in ❚Table 2❚. With "recurrences and/or death" as the classification variable, ROC analysis revealed the following cutoff points for each MI as the most appropriate: H&E MI, 4 or more per 10 HPF; and PHH3 MI, 6 or more per 10 HPF. The Ki-67 LI did not reach significance in the ROC analysis. However, at the expense of a low sensitivity, a Ki-67 LI exceeding 8% indicated recurrence or death with high specificity.
With only "recurrence" as the classification variable, a PHH3 MI of 4 or more per 10 HPF or an H&E MI of 4 or more per 10 HPF significantly indicated cases at risk of recurrence. The PHH3 MI was more sensitive in the prediction of recurrence probability than the traditional H&E MI. Three recurrent cases, which otherwise would have been ignored by the traditional mitosis counting method, could be therefore identified by regarding the PHH3 MI. However, both MIs were significantly superior to the Ki-67 LI in the discrimination between recurrent and nonrecurrent cases, as revealed by comparative ROC analyses (H&E MI vs Ki-67 LI, P = .022; PHH3 MI vs Ki-67 LI, P = .015). The highest discriminatory power among the proliferation indices is suggested for the PHH3 MI, which exhibits the greatest areas under the curve and the smallest P values by the Mann-Whitney U test.
The results of the log-rank test for H&E MI, PHH3 MI, and Ki-67 LI are summarized in ❚Table 3❚, and Kaplan-Meier curves are displayed in ❚Figure 2❚. Univariate analyses revealed a significantly higher risk of recurrence and/or death for higher proliferation, as measured by all 3 methods. The hazard ratios were 2.1 for an H&E MI of 4 or more per 10 HPF, 2.3 for a PHH3 MI of 6 or more per 10 HPF, and 7.6 for a Ki-67 LI of more than 8%. Results of multivariate Cox hazards modeling are summarized in ❚Table 4❚. H&E MI and PHH3 MI could be identified as independent predictors of worse outcome (recurrence and/or death), adjusted for age and extent of tumor resection (with STR as the independent variable). The Ki-67 LI did not reach significance in the multivariate setting.
Discussion
The 3-step grading system of meningiomas, distinguishing well-differentiated, atypical, and malignant meningiomas by the guidelines suggested by the WHO admits risk estimation based on histomorphologic criteria. Among the proposed negative prognostic factors, the degree of proliferation of tumor cells is known to be the most reliable and objective histopathologic parameter. 3 By following the instructions for the assessment of the MI as suggested by the WHO, we found the same mitotic threshold of an MI of 4 or more per 10 HPF as the most appropriate cutoff point for defining meningiomas with higher risk of recurrence or death, as proposed by the WHO. Cox regression analysis also revealed the H&E MI as an independent predictor of worse outcome, as suggested by Perry et al. 3 However, in practice MF counting in H&E-stained slides turned out to be a time-consuming and tedious task, in particular because in many cases the MFs had to be carefully searched at high power over the whole slide.
Another quantitative indicator of proliferation activity is the Ki-67 LI, which is determined as the percentage of Ki-67 positively stained tumor cell nuclei. The Ki-67 antigen is a nonhistone nuclear protein that is expressed in cycling cells. The determination of the Ki-67 LI has the advantage over the assessment of the H&E MI that the immunolabeled nuclei can be identified much easier than MFs in H&E-stained slides. The prognostic significance of the Ki-67 LI and other proliferation indices in meningiomas is well known. [15] [16] [17] [18] [19] [20] According to the current WHO grading system, meningiomas with high proliferation indices, ie, Ki-67 LI more than 5% to 10%, should be classified as meningiomas with a greater likelihood of recurrence and/or aggressive behavior, whereas no universal values have been specified for determining recurrence risk. This is due to a remarkably wide range of Ki-67 LI values suggested as prognostic cutoff levels among studies, owing to different staining techniques and counting methods. 15 We found a highly significant association of recurrent meningiomas and Ki-67 LI levels exceeding 8%. This threshold value is comparable with the mean Ki-67 LI value of 7.2% for atypical meningiomas mentioned by Maier et al 16 and cited by the WHO and also with the threshold value of a Ki-67 LI more than 10%, proposed by Ho et al 17 and Torp et al, 18 for distinguishing recurrent from nonrecurrent meningiomas. However, as mentioned by others, 19, 20 there is remarkable overlap of Ki-67 LI values among meningioma grades and recurrent/nonrecurrent meningiomas. Accordingly, despite the high specificity of 94% in the detection of recurrent meningiomas, our results suggest insufficient sensitivity because only 6% of recurrent cases exceeded the threshold level of a Ki-67 LI of more than 8%. Comparative ROC and multivariate analyses also revealed a significantly higher discriminatory power and predictive value for both MIs compared with the Ki-67 LI. However, as suggested in previous reports, 15, 19 the Ki-67 LI could be applied as a useful ancillary study for meningiomas with "borderline atypia."
To overcome the mentioned difficulties and limitations of yet existing quantitation methods of proliferation activity, in the present study, the applicability and prognostic significance of the PHH3 MI was evaluated. At present, to our knowledge (based on PubMed query), this is the largest series of tumor samples immunohistochemically studied for PHH3.
In our experience, the anti-PHH3-labeled MF counting method could be proved a rapid, facile, and sensitive method for the assessment of mitotic activity. The identification of the hot spot areas was much easier and more reproducible because the MFs were clearly visible at lower magnification. We systematically investigated the evaluation of the PHH3 MI at low power and compared the results with those obtained by summing the MFs at high magnification. The assessment of the PHH3 MI at low magnification was much faster and as reliable as the traditional summing in 10 consecutive areas at high magnification. Labeled objects that are not clearly identifiable as MFs at low magnification had to be specified at high power. However, this procedure was less tedious and time-consuming than the summing of MFs at high power. There were neither significant deviations in the mitotic counts nor changes in grade when both PHH3+ MF counting methods were compared with each other. The assessment of the PHH3 MI at low magnification can be suggested as the fastest way to reliably assess the MI in meningiomas.
The major advantage of PHH3 labeling is the clear and unambiguous distinction of MFs from other chromatin changes, which permits objective, reliable, and reproducible identification of MFs. We, therefore, confirm the results of previous reports, 4, [10] [11] [12] in which the advantages of MF counting in anti-PHH3-immunostained tumor specimens over the conventional MF counting method are described. Our results also confirm the higher sensitivity in the identification of MFs by using PHH3 immunoreaction as reported by Ribalta et al. 12 They reported a higher sensitivity of the PHH3 mitosis counting method, which resulted in an increase in tumor grade in 17% of cases studied.
Likewise, PHH3+ MF counting provided higher MIs in all 3 meningioma grades and an increase in tumor grade in 10.6% (28/265) of cases in our series. Allowing for this higher sensitivity of the PHH3 mitosis counting method, the mitotic thresholds proposed by the WHO have to be reconsidered if PHH3 MIs are applied to tumor grading. Accordingly, the threshold level at a PHH3 MI of 4 or more per 10 HPF did not reach significance in the univariate recurrence-free survival analysis.
Perry and coworkers 3 defined the threshold value of 4 or more mitoses per 10 consecutive HPF based on the results of multivariate survival analyses on H&E-stained tumor specimens. In the present study, multivariate Cox hazards modeling technique identified the PHH3 MI as an independent predictor of recurrence-free survival with the highest sensitivity in the detection of recurrent cases among proliferation indices. By using discriminant analyses, prognostic PHH3-specific threshold values could be defined, which permits a distinction between each risk group, or rather, tumor grade. However, as it holds for Ki-67 and other immunohistochemical markers of proliferation, there is variability between laboratories in terms of staining results and interpretation of anti-PHH3 immunoreactions. Thus, it is difficult to define universal cutoffs for 
